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Prognostic scores for hepatocellular carcinoma: none is the winner
Cancer classiﬁcation and indication of treatment are critical
steps in the management of patients with hepatocellular carci-
noma (HCC). The prediction of outcome is relevant to provide
adequate information to patients and relatives, both at the time
of treatment selection and after the application of therapy.
Tumour staging describes the extent of an individual’s tumour
burden in theoriginalprimary organ andspread throughout the
body, and other cofactors such as age or histological grade are
onlyseldomconsidered.Thisiscommontoallmalignanciesand
diseases. However, whereas for most neoplasms prognosis and
treatment are largely dictated by tumour stage at the time of
diagnosis, the scenario is more complex in patients with HCC.
It is well known that cirrhosis underlies HCC in most of the
patients and the functional impairment of the underlying liver
has a signiﬁcant impact on prognosis, irrespective of the
tumour stage. Moreover, liver function deﬁnes the capacity to
indicate treatments with potential deleterious effects on the
liver (1). This is well established in early tumours, in which
resection may be contraindicated because of the deterioration
of liver functional status and the same applies to patients with
multifocal HCC that could be considered for locoregional
therapies such as chemoembolization, in whom liver decom-
pensation unequivocally argues against its indication.
Several staging systems have been developed for the classiﬁ-
cation of patients with HCC. The best known and assessed
include eight systems based on clinical items: Okuda (2),
Cancer of Liver Italian Program (CLIP) (3), Barcelona Clinic
Liver Cancer (BCLC) (4), GRoupe d’Etude et de Traitement du
Carcinoma H´ epatocellulaire (GRETCH) (5), Tumour node
metastasis (TNM) (6), Chinese University Prognostic Index
(CUPI) (7), Japanese Integrated System (JIS) (8) and one
molecular staging system, the estrogen receptor (ER) (9)
classiﬁcation proposed by Villa et al.
A major problem of the studies on prediction of patient
outcomes from HCC on cirrhosis arises from a lack of
prognostic tools able to adequately express the medical com-
plexity of the syndrome. These tools could support an objective
risk stratiﬁcation in interventional studies, quality of care
evaluation and allocation of health care resources. Unfortu-
nately, no accurate mortality risk estimate is yet available to the
hepatologist as decision-making support in order to avoid
unethical and futile care of HCC patients. For instance, if the
difference in overall survival with or without a new molecular-
targeted therapy can be measured only in days or a few weeks,
and liver transplantation is not an option, the need for
intervention should be questioned.
The Okuda system (2) was developed about 20 years ago
based on data from advanced HCC patients. It includes tumour
size (occupying more or o50% of the liver) and three
indicators of the severity of cirrhosis (ascites, serum albumin
and bilirubin levels), but lacks important tumour factors, such
as portal vein thrombosis, size and number of neoplastic
lesions. A major issue of this system is that the assessment of
tumour burden is applicable only to the advanced stage. The
CLIP (3), GRETCH (5) and CUPI (7) systems were derived in
different cohorts of patients with HCC identifying survival
factors by multivariate analyses. The BCLC (4) staging system
uses variables related to tumour stage, liver functional status
and physical status. It is important to underline that the BCLC
is not a prognostic model able to assess the mortality of HCC
patients; instead, it is an allocation algorithm that, combining
independent prognostic factors in four different stages (from A
to D), links these stages with the best treatment option. The
American Joint Committee on Cancer (AJCC) TNM staging
system (6) considers the presence and the degree of severe
cirrhosis or ﬁbrosis to stratify outcome for every tumour (T)
classiﬁcation. The AJCC staging is the only one that is validated
in patients treated with either hepatic resection or transplanta-
tion and is however rarely used in Europe. The JIS (8) is a new
score system that includes two previous classiﬁcations: the TNM
endorsed by the Union Internationale Contre le Cancer, mostly
applied in Japan, and the Child–Pugh classiﬁcation. It lacks
external validation in western countries. Finally, a variant form
of the wild-type estrogen receptor has been identiﬁed in some
patients with HCC in which the receptor maintains constitutive
transcriptional activity. Tumours containing this variant tend to
bemore aggressive,withshorterdoublingtimes.Thepresenceof
variant estrogen receptors was a better predictorof an unfavour-
able prognosis compared with the CLIP and Barcelona. ER
classiﬁcation is not used routinely cause the need to perform
nodule biopsy to test for the variant receptor (9).
Among all these prognostic scores, the BCLC and the CLIP
are the most widely used and have been extensively validated in
different geographical settings, although the adoption, in gen-
eral, of one system appears to vary from country to country. We
demonstrated in a large prospective unicentre study that the
overall predictive ability of the BCLC and CLIP staging systems
was not satisfactory and was not uniform for treated and
untreated patients. None of the scoring systems provided a
conﬁdent prediction of survival in individual patients (10). In
our study, CLIP achieved the best discriminative capacity in the
advanced untreatable cases whereas BCLC was the most able in
predicting survival in treated patients. Similarly, a recent study
(11)published in this journal conﬁrmed that in a large cohort of
about 4000 treated patients, the discriminatory ability of the
CLIP score was modest for the early HCC stages. In particular,
the CLIP-scoring system demonstrates signiﬁcant interscore
prognostic prediction. However, different prognostic weighting
of four predictive factors may cause intragroup heterogeneity.
The lower the CLIP score, the greater the intragroup difference.
The authors’ conclusion was that the CLIP-staging scoring
system was a reasonable ordinal scale, but the clinician must be
aware of the heterogeneity of mortality risk within a given score.
We fully agree with the conclusions of the Editorial by Ray
Kimpublished in Liver International, whowrote that ‘No model
is perfect and the utility of the current available prognostic
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homogeneity (precision) and discrimination of all the available
prognostic scores are far from perfect and different lines of
evidence suggest that none of these staging systems provided
sufﬁcient conﬁdence for the prediction of outcomes in indivi-
dual patients. Thus, no system has been recommended world-
wide for clinical purposes (1) and a high degree of caution must
be exerted in the clinical application of the existing models for
outcome prediction in HCC patients.
Why, when validated internally or externally, does none of
these staging systems provide sufﬁcient conﬁdence for the
prediction of outcome in individual patients? Many factors,
linked to the model’s characteristics and the complexity of the
disease, may contribute to a less than satisfactory performance.
Possible biases are exempliﬁed by heterogeneity in diagnostic
criteria, time to diagnosis of HCC, time of referral or lead-time
bias, true differences in case mix, presence and absence of the
underlying cirrhosis and its aetiology and severity and systema-
tic differences in the effectiveness of treatment algorithms. An
important question concerning studies on prediction of mor-
tality of HCC is that these studies were designed to combine a
wide spectrum of patients – those with early, intermediate,
advanced and end-stage HCC – pooling treatable and untrea-
table subjects. These studies compare the overall predictive
ability of the different general patient models in the entire
spectrum of patients to identify the best staging system rather
than to allow the performance of those same models to be
analysed in more homogeneous subgroups of patients with
HCC (e.g. potentially treatable vs. untreatable subjects) (10).
When there is evidence that a given general model is not fully
appropriate for outcome prediction in a particular clinical
setting, a possible solution can be represented by the use of
specialized models evaluating patient outcomes within speciﬁc
allocation treatment groups (i.e. liver transplantation, percuta-
neous ablation, resection,transarterial embolization/chemoem-
bolization and systemic therapies). However, a relevant
shortcoming in predicting outcome in the setting of treated
patients is due to the fact that the assessment of the beneﬁt of
the different treatments on overall survival by any staging
system adds more complexity to the already high degree of
epidemiological, biological and clinical heterogeneity of pa-
tients with HCC before treatment. Lastly, it is very difﬁcult to
evaluate the interaction between the different treatments and
baseline prognostic variables and its own impact on overall
survival. As a consequence, the ideal staging system able to link
staging with treatment allocation and to predict the impact of
treatment on life expectancy in the whole spectrum of patients
with HCC today remains an elusive goal.
In the current issue of Liver International, Tandon et al. (13)
performed a methodologically sound systematic review of the
literature evaluating predictors of death in patients with
cirrhosis and HCC, aiming to evaluate whether predictors
today differ between patients with compensated and decom-
pensated cirrhosis. A large number of studies (72), published as
full-length papers, were quoted. This systematic review, with a
total of 23968 patients included, shows that there are very
heterogeneous study designs. In fact, 71% of the studies were
retrospective and only 29% were prospective. Only 57% of the
studies enrolled patients consecutively. The best predictors of
death in patients with cirrhosis and HCC are tumour and liver
related. A total of 79 variables were evaluated in these studies.
The most common independent predictors of death in HCC
were portal vein thrombosis, tumour size, a-fetoprotein (AFP),
the Child–Pugh class, bilirubin and the CLIP score.
When the 22 studies in whom 100% of the patients had
cirrhosis were analysed, the most common predictors of death
were the CLIP score, tumour size, the Child–Pugh class, tumour
number, AFP and portal vein thrombosis. When patients were
separated by advanced or nonadvanced tumour status, the most
important predictorsof death in patients with advancedtumours
wereportalveinthrombosis,AFP,bilirubinandlackoftreatment.
Although the number of studies that included mostly
compensated or decompensated cirrhotic patients was small,
the ﬁrst important conclusion of this review, which needs
further conﬁrmations, is that in the compensated patients,
factors related to the tumour wouldbe more important whereas
in the decompensated patient, both liver- and tumour-related
factors would be important.
The second and relevant ﬁnding of the study by Tandon et al.
is to suggest that different predictors should be performed in
speciﬁc patient populations to obtain a better prediction of
death. We believe that this is an important attempt of customi-
zation of the available general prognostic models. A problem
with this systematic review is that there are limitations in the
data, which are beyond the authors’ control. These include the
lack of a standardized diagnostic criteria and staging proce-
dures, the heterogeneity among studies in population charac-
teristics and prevalence of compensated or decompensated
cirrhosis. The authors are very fair in pointing out these
limitations and the resultant limitations on the conclusions
that may be drawn from summary data in the discussion.
Growing experimental evidences suggest that there are well-
known factors not accounted for in the prognostic models that
canhavesome impact on patient outcomes,both in early as well
as in advanced stages.
Global gene expression proﬁling may be the most appro-
priate technology to explore its heterogeneous origin. In fact,
application of gene expression proﬁling of HCC represents a
promising progress in elucidating the molecular pathogenesis
of HCC and in improving the prognostic prediction for HCC
patients.
In conclusion, we truly need new and more accurate prog-
nostic models that include important, although still unknown,
biological variables and models that account for changes during
the course of the disease.
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